Clinical trials are a very important part of the research process. New treatments, medications and medical devices cannot be approved for use in Australia without going through clinical trials. Find out more about clinical trials.
Novel treatment for non-alcoholic fatty liver disease
A trial to test the effectiveness of a novel non-invasive treatment for fatty liver disease.
This research study aims to get more information on how a weekly insulin (insulin icodec) helps in reducing blood sugar compared to insulin glargine, an insulin taken once daily, in adults with type 1 diabetes, who are also taking a mealtime insulin (insulin aspart).
OPT-302 with ranibizumab for neovascular age-related macular degeneration
The ShORe trial aims to determine if the investigational medication OPT-302 will improve vision for people with wet age-related macular degeneration (AMD) when given in combination with ranibizumab, compared to ranibizumab alone.
Optimised Transcranial Magnetic Stimulation (OptiTMS) trial for the treatment of depression investigates whether personalised brain stimulation targeting can improve outcomes for people with major depressive disorder.
Perampanel to control and prevent seizures in patients with brain tumours
A randomised controlled trial assessing the safety and effectiveness of perampanel, an anti-epileptic drug, in people with brain tumours.
Possible new drug for Crohn’s disease
We aimed to determine the safety and effectiveness of a new study medication, guselkumab, for people with Crohn's disease
Possible treatment for Parkinson’s disease
Cerevel Therapeutics has begun a study of an experimental drug called CVL-751 as a possible treatment for people with Parkinson’s disease.
PRAX-944 as a potential treatment for essential tremor
A clinical trial evaluating the efficacy, safety, tolerability, and pharmacokinetics of PRAX-944 in adults with essential tremor.
The Prurigo Nodularis trial aims to assess the safety and effectiveness of a treatment to assist in reducing symptoms for people living with this condition
Phase 3 study to assess efficacy, safety and tolerability of a study treatment in adult patients with moderate to severe hidradenitis suppurativa (HS).
REIMAGINE-4: A clinical trial to help with glucose control and weight loss
With REIMAGINE-4, we are comparing a potential new weight loss treatment called CagriSema to Tirzepatide (also known as Mounjaro®) in people with Type 2 Diabetes
Remibrutinib for chronic spontaneous urticaria
A clinical trial to assess a new drug for chronic spontaneous urticaria (CSU) not controlled with antihistamine medication or omalizumab (Xolair®) in the past.
Researching better treatment for Focal Segmental Glomerulosclerosis and Minimal Change Disease
This study is testing three new treatments for people who have Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD).
Ritlecitinib in adults with non-segmental vitiligo
This trial is investigating a medication for treating people living with non-segmental vitiligo.
Seladelpar as a treatment for primary biliary cholangitis (PBC)
A study to evaluate the safety and effectiveness of an investigational drug, seladelpar, in treating patients with primary biliary cholangitis (PBC).
Sodium selenate for probable behavioural variant frontotemporal dementia
A trial to test sodium selenate as a disease-modifying treatment for probable behavioural variant frontotemporal dementia (bvFTD).
Spesolimab for the treatment of generalised pustular psoriasis
A study to test whether spesolimab prevents flare-ups in patients with generalised pustular psoriasis.
Spesolimab for the treatment of hidradenitis suppurativa
A study to measure how safe and effective spesolimab (the study drug) is in treating participants with moderate to severe hidradenitis suppurativa (HS).
Study to reduce heart risks in people on dialysis with diabetes or heart disease
This is a dose-finding and cardiovascular outcomes study of the study treatment in adults with end-stage kidney disease (ESKD) undergoing dialysis
Study to understand risk of Alzheimer’s disease in middle-aged adults
An Australian-first online study of psychological, lifestyle and genetic factors that increase risk of Alzheimer’s disease.
Swabs required for research to develop point-of-care testing for infectious diseases
ZiP Diagnostics requires human samples for research into developing point-of-care (PoC) diagnostic tests for a range of infectious diseases.
The AUTUMN study: researching a new medicine for membranous nephropathy
This study is testing a new medicine called ALXN1920 for people with a kidney disease called membranous nephropathy.
Almost 1 in 3 people diagnosed with depression – or Major Depressive Disorder (MDD) – do not notice an improvement in their symptoms after trying at least two of the antidepressant drugs available today. This is known as Treatment-Resistant Depression (TRD).
The Elumina study is researching a study drug for people with TRD to learn if it may improve their symptoms of depression.
This study is to test the safety and effectiveness of FB102 in well-controlled coeliac disease (those on a strict gluten free diet) following a gluten consumption challenge.
This study is for people with a kidney condition called IgA nephropathy (IgAN), especially those at risk of their condition getting worse.
The Kite trial is investigating whether low-dose ketamine is effective in reducing depressive symptoms in adults with bipolar depression.
Since 2023, the international recommendation is either medication or surgery as first-line therapy for small and well-localised prolactinomas. However, there is a lack of prospective studies comparing outcomes and evaluating quality of life.
This trial is testing a study drug to see if it can safely reduce the harmful effects of alcohol on the liver.
This research study aims to see how well the study treatment, a drug-device combination performs as a possible treatment for diabetic peripheral neuropathic pain.
The TRANSCEND study – testing a new medicine for kidney transplant rejection
This study is testing a new medication called felzartamab for people who have received a kidney transplant and developed a type of rejection called late antibody-mediated rejection (AMR).